Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of avelumab + cetuximab + radiotherapy versus standard of care in locally advanced squamous cell carcinoma of the head and neck
2016-004383-19Phase 3Active
- Sponsor
- GORTEC
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of avelumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by GORTEC. Primary endpoint: Progression-free survival. Started Sep 2017; status: active.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-004383-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004383-19.